Premium
Immune‐mediated thrombocytopenia resulting from sensitivity to oxaliplatin
Author(s) -
Curtis Brian R.,
Kaliszewski James,
Marques Marisa B.,
Saif M. Wasif,
Nabelle Lisle,
Blank Jules,
McFarland Janice G.,
Aster Richard H.
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20516
Subject(s) - oxaliplatin , medicine , platelet , chemotherapy , bone marrow , immunology , immune system , colorectal cancer , gastroenterology , oncology , cancer
Thrombocytopenia developing in the course of chemotherapy for malignant disease is usually attributed to drug‐induced marrow suppression and/or marrow replacement by tumor. We describe two patients who developed severe thrombocytopenia and hemorrhagic symptoms while being treated with oxaliplatin, 5‐fluorouracil, and leukovorin for metastatic colon cancer in whom platelet destruction appears to have been caused by oxaliplatin‐dependent antibodies specific for the platelet glycoprotein IIb/IIIa complex (α IIb /β 3 integrin). Drug‐induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow. Am. J. Hematol. 81:193–198, 2006. © 2006 Wiley‐Liss, Inc.